Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Olle Melander

Principal investigator

Default user image.

Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease

Author

  • Jacy Crosby
  • Gina M. Peloso
  • Paul L. Auer
  • David R. Crosslin
  • Nathan O. Stitziel
  • Leslie A. Lange
  • Yingchang Lu
  • Zheng-zheng Tang
  • He Zhang
  • George Hindy
  • Nicholas Masca
  • Kathleen Stirrups
  • Stavroula Kanoni
  • Ron Do
  • Goo Jun
  • Youna Hu
  • Hyun Min Kang
  • Chenyi Xue
  • Anuj Goel
  • Martin Farrall
  • Stefano Duga
  • Pier Angelica Merlini
  • Rosanna Asselta
  • Domenico Girelli
  • Oliviero Olivieri
  • Nicola Martinelli
  • Wu Yin
  • Dermot Reilly
  • Elizabeth Speliotes
  • Caroline S. Fox
  • Kristian Hveem
  • Oddgeir L. Holmen
  • Majid Nikpay
  • Deborah N. Farlow
  • Themistocles L. Assimes
  • Nora Franceschini
  • Jennifer Robinson
  • Kari E. North
  • Lisa W. Martin
  • Mark DePristo
  • Namrata Gupta
  • Stefan A. Escher
  • Jan-Hakan Jansson
  • Natalie Van Zuydam
  • Colin N. A. Palmer
  • Nicholas Wareham
  • Werner Koch
  • Thomas Meitinger
  • Annette Peters
  • Wolfgang Lieb
  • Raimund Erbel
  • Inke R. Konig
  • Jochen Kruppa
  • Franziska Degenhardt
  • Omri Gottesman
  • Erwin P. Bottinger
  • Christopher J. O'Donnell
  • Bruce M. Psaty
  • Christie M. Ballantyne
  • Goncalo Abecasis
  • Jose M. Ordovas
  • Olle Melander
  • Hugh Watkins
  • Marju Orho-Melander
  • Diego Ardissino
  • Ruth J. F. Loos
  • Ruth McPherson
  • Cristen J. Willer
  • Jeanette Erdmann
  • Alistair S. Hall
  • Nilesh J. Samani
  • Panos Deloukas
  • Heribert Schunkert
  • James G. Wilson
  • Charles Kooperberg
  • Stephen S. Rich
  • Russell P. Tracy
  • Dan-Yu Lin
  • David Altshuler
  • Stacey Gabriel
  • Deborah A. Nickerson
  • Gail P. Jarvik
  • L. Adrienne Cupples
  • Alex P. Reiner
  • Eric Boerwinkle
  • Sekar Kathiresan

Summary, in English

Background Plasma triglyceride levels are heritable and are correlated with the risk of coronary heart disease. Sequencing of the protein-coding regions of the human genome (the exome) has the potential to identify rare mutations that have a large effect on phenotype. Methods We sequenced the protein-coding regions of 18,666 genes in each of 3734 participants of European or African ancestry in the Exome Sequencing Project. We conducted tests to determine whether rare mutations in coding sequence, individually or in aggregate within a gene, were associated with plasma triglyceride levels. For mutations associated with triglyceride levels, we subsequently evaluated their association with the risk of coronary heart disease in 110,970 persons. Results An aggregate of rare mutations in the gene encoding apolipoprotein C3 (APOC3) was associated with lower plasma triglyceride levels. Among the four mutations that drove this result, three were loss-of-function mutations: a nonsense mutation (R19X) and two splice-site mutations (IVS2+1G -> A and IVS3+1G -> T). The fourth was a missense mutation (A43T). Approximately 1 in 150 persons in the study was a heterozygous carrier of at least one of these four mutations. Triglyceride levels in the carriers were 39% lower than levels in noncarriers (P<1x10(-20)), and circulating levels of APOC3 in carriers were 46% lower than levels in noncarriers (P = 8x10(-10)). The risk of coronary heart disease among 498 carriers of any rare APOC3 mutation was 40% lower than the risk among 110,472 noncarriers (odds ratio, 0.60; 95% confidence interval, 0.47 to 0.75; P = 4x10(-6)). Conclusions Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have a reduced risk of coronary heart disease. (Funded by the National Heart, Lung, and Blood Institute and others.)

Department/s

  • Diabetes - Cardiovascular Disease
  • Cardiovascular Research - Hypertension
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year

2014

Language

English

Pages

22-31

Publication/Series

New England Journal of Medicine

Volume

371

Issue

1

Document type

Journal article

Publisher

Massachusetts Medical Society

Topic

  • Cardiac and Cardiovascular Systems
  • Endocrinology and Diabetes

Status

Published

Research group

  • Diabetes - Cardiovascular Disease
  • Cardiovascular Research - Hypertension

ISBN/ISSN/Other

  • ISSN: 0028-4793